›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:oncoReveal™ Solid Tumor v2 Panel
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Pillar BiosciType:
Laboratory Developed Test
Related tests:
The oncoReveal™ Solid Tumor v2 Panel is a robust 48-gene assay that simultaneously tests for key
mutations present in solid tumors, including NSCLC, colorectal, melanoma, endometrial, pancreatic, GIST,
bladder, thyroid, and gliomas. Additionally, genes with potential importance in immuno-oncology such as
POLD1 and POLE are analyzed. The panel uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp®) technology, a tiled amplicon-based library prep chemistry for efficient single-tube target enrichment.
Cancer:
Bladder Cancer, Colorectal Cancer, Endometrial Cancer, Gastrointestinal Stromal Tumor, Glioma, Melanoma, Non Small Cell Lung Cancer, Pancreatic Cancer, Solid Tumor, Thyroid Gland Carcinoma
Gene:
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), ARAF (A-Raf Proto-Oncogene), BRAF (B-raf proto-oncogene), CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), CTNNB1 (Catenin (cadherin-associated protein), beta 1)
See More ...
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), ARAF (A-Raf Proto-Oncogene), BRAF (B-raf proto-oncogene), CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), CTNNB1 (Catenin (cadherin-associated protein), beta 1), CYSLTR2 (Cysteinyl Leukotriene Receptor 2), DDR2 (Discoidin domain receptor 2), EGFR (Epidermal growth factor receptor), EIF1AX (Eukaryotic Translation Initiation Factor 1A X-Linked), ERBB4 (erb-b2 receptor tyrosine kinase 4), FBXW7 (F-Box And WD Repeat Domain Containing 7), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), GNA11 (G Protein Subunit Alpha 11), GNAQ (G Protein Subunit Alpha Q), GNAS (GNAS Complex Locus), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), KEAP1 (Kelch Like ECH Associated Protein 1), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), MAP2K1 (Mitogen-activated protein kinase kinase 1), MET (MET proto-oncogene, receptor tyrosine kinase), NRAS (Neuroblastoma RAS viral oncogene homolog), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), PLCB4 (Phospholipase C Beta 4), POLD1 (DNA Polymerase Delta 1), POLE (DNA Polymerase Epsilon), PTEN (Phosphatase and tensin homolog), PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11), RAC1 (Rac Family Small GTPase 1), RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase), RET (Ret Proto-Oncogene), SF3B1 (Splicing Factor 3b Subunit 1), SMAD4 (SMAD family member 4), SRSF2 (Serine and arginine rich splicing factor 2), STK11 (Serine/threonine kinase 11), TERT (Telomerase Reverse Transcriptase), TP53 (Tumor protein P53)
Method:
Next-Generation Sequencing (NGS)
